Helman Samuel N, Schwedhelm Thomas, Kadakia Sameep, Wang Yanhua, Schiff Bradley A, Smith Richard V
From the Department of Otolaryngology/Head and Neck Surgery, New York Eye and Ear Infirmary-Mount Sinai Health System, New York, New York (Drs Helman and Kadakia); Albert Einstein College of Medicine, Bronx, New York (Mr Schwedhelm); and the Departments of Pathology (Dr Wang) and Otorhinolaryngology-Head and Neck Surgery (Drs Schiff and Smith), Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Arch Pathol Lab Med. 2015 Nov;139(11):1389-97. doi: 10.5858/arpa.2014-0573-RA. Epub 2015 Aug 19.
The incidence of oropharyngeal squamous cell carcinoma has increased during the past decade and is related primarily to the human papillomavirus. This change in etiology, from tobacco and alcohol to human papillomavirus, has resulted in improved survival for the disease. In the United States, open resection had largely been replaced by concurrent chemotherapy and/or radiotherapy by the early 2000s. The advent of transoral surgery has led to an increase in surgery as the primary treatment for both early- and advanced-stage oropharyngeal squamous cell carcinoma because it has potential advantages over open surgery and nonsurgical modalities.
To provide an overview of transoral robotic surgery for oropharyngeal squamous cell carcinoma and contrast it with other surgical and nonsurgical modalities.
Articles from 2000 to 2014 were accessioned on PubMed and reviewed for utility by the primary authors.
Transoral surgery has become more commonly used as a minimally invasive approach to treat oropharyngeal tumors. Other strategies, including radiation, chemotherapy with radiation, and open surgery, are still important treatment approaches. The treatment options for an individual patient rely on multiple factors, including the tumor location and size, features of the tumor, and patient comorbidities. The continued study of these techniques is important to match the patient with the most appropriate treatment.
在过去十年中，口咽鳞状细胞癌的发病率有所上升，且主要与人乳头瘤病毒有关。病因从烟草和酒精转变为人乳头瘤病毒，这使得该疾病的生存率得到了提高。在美国，到21世纪初，开放性切除术在很大程度上已被同步放化疗所取代。经口手术的出现使得手术作为早期和晚期口咽鳞状细胞癌的主要治疗方法的应用有所增加，因为它相对于开放性手术和非手术方式具有潜在优势。
概述经口机器人手术治疗口咽鳞状细胞癌的情况，并将其与其他手术和非手术方式进行对比。
2000年至2014年的文章在PubMed上收录，并由第一作者对其实用性进行了审查。
经口手术已越来越普遍地作为一种微创方法用于治疗口咽肿瘤。其他策略，包括放疗、放化疗以及开放性手术，仍然是重要的治疗方法。个体患者的治疗选择取决于多种因素，包括肿瘤的位置和大小、肿瘤特征以及患者的合并症。持续研究这些技术对于为患者匹配最合适的治疗方法很重要。
